Hubbry Logo
MethylecgonidineMethylecgonidineMain
Open search
Methylecgonidine
Community hub
Methylecgonidine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Methylecgonidine
Methylecgonidine
Methylecgonidine
View on Wikipedia
from Wikipedia
Methylecgonidine
Names
IUPAC name
Methyl trop-2-ene-2β-carboxylate
Systematic IUPAC name
Methyl (1R,5S)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene-2-carboxylate
Other names
Anhydromethylecgonine
Anhydroecgonine methyl ester
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.164.719 Edit this at Wikidata
UNII
  • InChI=1S/C10H15NO2/c1-11-7-3-5-8(10(12)13-2)9(11)6-4-7/h5,7,9H,3-4,6H2,1-2H3/t7-,9+/m0/s1 checkY
    Key: MPSNEAHFGOEKBI-IONNQARKSA-N checkY
  • InChI=1/C10H15NO2/c1-11-7-3-5-8(10(12)13-2)9(11)6-4-7/h5,7,9H,3-4,6H2,1-2H3/t7-,9+/m0/s1
    Key: MPSNEAHFGOEKBI-IONNQARKBC
  • CN2[C@@H]/1CC[C@@H]2C\C=C\1C(=O)OC
Properties
C10H15NO2
Molar mass 181.235 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Methylecgonidine (anhydromethylecgonine; anhydroecgonine methyl ester; AEME) is a chemical intermediate derived from ecgonine or cocaine.

Methylecgonidine is a pyrolysis product formed when crack cocaine is smoked, making this substance a useful biomarker to specifically test for use of crack cocaine, as opposed to powder cocaine which does not form methylecgonidine as a metabolite.[1] Methylecgonidine has a relatively short half-life of 18–21 minutes, after which it is metabolised to ecgonidine, meaning that the relative concentrations of the two compounds can be used to estimate how recently crack cocaine has been smoked. Methylecgonidine has been shown to be specifically more harmful to the body than other byproducts of cocaine; for example to the heart,[2] lungs[3] & liver.[4] The toxicity is due to a partial agonist effect at M1 and M3 muscarinic receptors, leading to DNA fragmentation and neuronal death by apoptosis.[5]

AEME is also used in scientific research for the manufacture of phenyltropane analogues such as troparil, dichloropane, iometopane, and CFT. Methylecgonidine could also theoretically be used to produce cocaine and so may be a controlled substance in some countries.

Synthesis

[edit]
Methylecgonidine synthesis from cocaine

Methylecgonidine can be synthesized non pyrolytically from cocaine via hydrolysis/dehydration[6] followed by esterification with methanol.[7][8]

Methylecgonidine synthesis by Kline

The scheme by Kline[9] is based on the reaction of 2,4,6-cycloheptatriene-7-carboxylic acid with methylamine. This is a modified version of U.S. patent 2,783,235 by Grundmann and Ottmann. In the accompanying patent U.S. patent 2,783,236 these same authors react their methylecgonidine with two equivalents of PhLi to form a tertiary alcohol by "hard" addition to the ester and not "soft" Michael addition. However, the product is only one tenth the potency of atropine. The methyl 2,4,6-cycloheptatriene-1-carboxylate can be made synthetically.[10][11]

Methylecgonidine synthesis by Davies. Enantioselective[12]

Davies et al. synthesized (R/S)-methylecgonidine by a tandem cyclopropanation/Cope rearrangement.[13][14] Thus, reaction of methyldiazobutenoate (2) with 5 equiv of N-((2-(TMS)ethoxy)carbonyl)pyrrole (1) in the presence of rhodium(II) hexanoate/hexane gave the [3.2.1]-azabicyclic system (R/S)-8 in 62% yield. The unsubstituted double bond was selectively reduced using Wilkinson catalyst to provide N-protected anhydroecgonine methyl ester ((R/S)-4). Following deprotection of N8 nitrogen with TBAF and reductive methylation with formaldehyde and sodium cyanoborohydride, (R/S)-5 was obtained in overall good yield.

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Methylecgonidine

View on Grokipedia
from Grokipedia

Methylecgonidine, also known as anhydroecgonine methyl ester (AEME), is a tropane alkaloid formed as the primary pyrolysis product when cocaine base is heated, such as during the smoking of crack cocaine. This compound arises through thermal decomposition of cocaine, distinguishing it from metabolites produced via other routes of administration like intranasal use of cocaine hydrochloride. Due to its specificity, methylecgonidine serves as a reliable biomarker for detecting crack cocaine use in biological samples such as urine and blood. Pharmacokinetically, methylecgonidine exhibits rapid clearance from blood with a half-life of 18 to 21 minutes, while its primary metabolite, ecgonidine, persists longer with a half-life of 94 to 137 minutes. It demonstrates higher vapor pressure than cocaine, leading it to coat crack particles during condensation in smoke. Notably, methylecgonidine exerts toxicity through partial agonism at M1 and M3 muscarinic receptors, inducing DNA fragmentation, apoptosis, and neuronal death, which may amplify the neurotoxic effects associated with smoked cocaine. This cholinergic activity contrasts with cocaine's primary mechanism and underscores methylecgonidine's independent contribution to the adverse outcomes of crack use, including potential airway and cardiovascular impacts.

Chemical Characteristics

Molecular Structure and Properties

Methylecgonidine, systematically named methyl (1R,5S)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene-2-carboxylate and also known as anhydroecgonine methyl ester (AEME), has the molecular formula C10H15NO2 and a molecular weight of 181.23 g/mol. It represents a dehydrated derivative of ecgonine methyl ester, featuring a tropane bicyclic core—a bridged 8-azabicyclo[3.2.1]octane system—with an N-methyl group, a Δ2 double bond in the five-membered ring, and a methyl carboxylate substituent at the 2-position. This structure lacks the 3-benzoyloxy ester present in cocaine, resulting in a simpler ester linkage solely at the carboxylate. The compound exhibits solubility in organic solvents, achieving 10 mg/mL in and slight solubility in and . Under standard conditions, methylecgonidine demonstrates chemical stability, though it undergoes in basic environments with pH greater than 5. Its tropane scaffold confers lipophilic character, reflected in computed partition coefficients, facilitating interactions typical of esters.

Physical and Spectroscopic Data

Methylecgonidine (C₁₀H₁₅NO₂) has a of 181.23 g/mol and exists as a liquid at . Safety data sheets report a of -46 °C and a of 81 °C, with a of 2 °C indicating high volatility and flammability. The predicted is 1.112 g/cm³, and it exhibits slight in . These properties contribute to its vaporization during , allowing it to coat particulate matter. In , methylecgonidine is commonly identified via gas chromatography-electron (GC-EI-MS), displaying a molecular at m/z 181 and characteristic fragments such as m/z 136 (from loss of the methoxycarbonyl group) and lower abundance at m/z 94 and 82 derived from ring cleavage. (NMR) spectra, available in public databases, confirm the structure with distinct proton shifts for the unsaturated ring and protons, typically analyzed in CDCl₃ solvent. (IR) spectroscopy reveals absorption bands consistent with the α,β-unsaturated , including a carbonyl stretch around 1710–1730 cm⁻¹, though specific spectra are primarily referenced in synthetic validation studies.
PropertyValueSource
Molecular formulaC₁₀H₁₅NO₂ChemSpider
Molar mass181.23 g/molChemSpider
Melting point-46 °CCayman SDS
Boiling point81 °CCayman SDS
Density (predicted)1.112 g/cm³ChemicalBook
Methylecgonidine demonstrates thermal stability sufficient for volatilization below 200 °C but undergoes at higher temperatures, consistent with its role as an intermediate product. studies indicate stability in frozen plasma (-80 °C) for extended periods, with minimal when preserved with .

Formation and Synthesis

Pyrolytic Formation from

Methylecgonidine, also known as anhydroecgonine methyl ester (AEME), forms primarily through the thermal of base during smoking, where temperatures exceed 200°C trigger the elimination of from the molecule via a trans-elimination mechanism. This process yields methylecgonidine as the dominant volatile pyrolysis product in the temperature range of 200–500°C, distinct from higher-temperature pathways above 500°C that involve alternative elimination routes. Unlike metabolic routes, this pyrolytic degradation is absent in non-smoked administration, making methylecgonidine a specific for inhalation exposure. Pyrolysis experiments conducted in the late and demonstrated that methylecgonidine accounts for a substantial fraction of cocaine's products, with yields reaching up to 89% of identified volatiles at 650°C under controlled volatilization conditions, alongside comprising 83%. In simulated smoking scenarios, such as heating cocaine base to mimic crack pipe starting around 170°C, methylecgonidine emerges as the major product, comprising significant in the resulting —often estimated at 30–40% under optimal conditions—while unpyrolyzed cocaine volatilizes separately. These findings from gas chromatography-mass spectrometry analyses confirm the pathway's efficiency in generating inhalable AEME absent in intravenous or intranasal use. The higher vapor pressure of methylecgonidine relative to cocaine base promotes its preferential volatilization during pyrolysis, leading it to condense and coat the surface of submicron crack particles (typically 0.5–1 μm in diameter) as they form in the smoke plume. This coating enhances aerosol stability and inhalation efficiency, as the volatile AEME layer prevents premature particle agglomeration and facilitates deeper lung deposition compared to larger particles produced by alternative heating methods like hot-wire volatilization. Empirical observations from 1990s aerosol studies underscore this mechanism's role in distinguishing smoked cocaine's delivery profile.

Laboratory Synthesis Methods

Methylecgonidine, also known as anhydroecgonine methyl ester (AEME), is primarily synthesized in the via dehydration of ecgonine methyl ester, which first requires esterification of with under acidic conditions to yield the ester precursor. This route employs , such as phosphorus oxychloride (POCl3) in or dimethylformamide, to eliminate the hydroxyl group at the 3-position, forming the endocyclic double bond characteristic of the tropene . The reaction proceeds at elevated temperatures, typically conditions, and is quenched with followed by basification and extraction to isolate the product. An improved synthesis protocol, developed in 1997, optimizes the POCl3-mediated by using controlled and systems, achieving yields up to 60-70% while minimizing side products. This method was refined to produce material suitable for spectroscopic confirmation, including electron impact (EI-MS) with a molecular at m/z 179 and fragmentation patterns matching those from pyrolytic samples, ensuring analytical equivalence without artifacts. For avoiding natural precursors, a tandem /Cope rearrangement sequence starting from methyl 2,4,6-cycloheptatriene-1-carboxylate has been reported, yielding racemic methylecgonidine after addition and thermal rearrangement at 110°C, followed by and esterification steps. This approach, detailed in 1994, provides access to stereoisomers for structure-activity studies but suffers from lower overall yields (around 20-30%) due to multiple transformations and requires chromatographic purification to achieve >95% purity. Purity challenges in these syntheses include the formation of isomeric anhydrides or dimeric byproducts, necessitating or ; high-purity samples (>98%) are essential to distinguish methylecgonidine from contaminants like derivatives in metabolic assays. These controlled methods enable reproducible production for research, with 1990s academic efforts, including NASA-funded validations, confirming identity via comparative MS and NMR data against crack smoke condensates.

Pharmacokinetics

Absorption, Distribution, and Elimination

Methylecgonidine (also known as anhydroecgonine methyl ester or AEME) is primarily absorbed through when formed as a product during smoking, owing to its volatility and deposition in the pulmonary alveoli. This route enables rapid entry into the bloodstream, with peak plasma concentrations achieved within minutes of exposure. Absorption efficiency increases in the presence of co-pyrolyzed , facilitating swift systemic uptake as a small, lipophilic . Distribution data for methylecgonidine remain limited, primarily derived from vapor exposure models in . It exhibits broad tissue distribution following pulmonary absorption, with notable accumulation in tissues due to initial alveolar deposition. Cardiovascular tissues may also receive early exposure based on , though quantitative volume of distribution metrics are not well-characterized in humans. Elimination of methylecgonidine occurs rapidly, with a plasma half-life of 18–21 minutes in pharmacokinetic models, exceeding the clearance rate of parent (which has a of approximately 45–90 minutes). Primary excretion is renal, with the unchanged compound and metabolites detectable in , supporting faster overall clearance than in both animal and exposure scenarios.

Metabolism to Ecgonidine

Methylecgonidine, also known as anhydroecgonine methyl ester (AEME), is primarily metabolized through hydrolytic cleavage of its methyl ester group, yielding ecgonidine (anhydroecgonine). This occurs via enzymatic mediated by plasma and hepatic esterases, with evidence also indicating potential contributions from chemical under alkaline conditions . Unlike , which undergoes dual ester including cleavage of the to form , methylecgonidine lacks a benzoyl moiety, restricting its metabolism to the single ester pathway and rendering ecgonidine a distinctive downstream specific to products. The plasma half-life of methylecgonidine is short, ranging from 18 to 21 minutes, facilitating rapid conversion to ecgonidine, which exhibits a prolonged of 94 to 137 minutes. This extended persistence of ecgonidine extends its detection window in biological fluids compared to the parent compound, aiding forensic and clinical assessments of use. In studies, ecgonidine has been identified as the predominant urinary derived from methylecgonidine in crack smokers, with analytical methods confirming its presence alongside trace methylecgonidine to verify smoking-specific exposure. Quantitative urinary profiling from controlled administrations demonstrates ecgonidine concentrations that correlate directly with methylecgonidine intake, underscoring its utility as a reliable indicator without interference from non-pyrolytic routes.

Pharmacodynamics and Biological Effects

Mechanism of Action

Methylecgonidine, also known as anhydroecgonine methyl ester (AEME), exerts its primary pharmacological effects through partial agonism at muscarinic acetylcholine receptors (mAChRs), distinguishing it from cocaine's mechanism of inhibition at the (DAT). Unlike , which exhibits high-affinity binding to DAT (Ki ≈ 0.6 μM) to block monoamine , methylecgonidine demonstrates negligible inhibition of uptake, with binding affinities for monoamine transporters orders of magnitude lower, as evidenced by its lack of reinforcing effects akin to in behavioral assays. At M1 and M3 mAChRs, which couple to proteins, methylecgonidine acts as a with binding affinities of Ki = 25.7 μM (M1) and Ki = 33.9 μM (M3), eliciting concentration-dependent activation of (PLC). This pathway increases () production, mobilizing intracellular Ca²⁺ stores and elevating cytosolic Ca²⁺ levels (EC₅₀ > 100 μM, achieving 38.3% of maximal response at M1 and 27.2% at M3). In neuronal contexts, this signaling contributes to downstream effects via PLC inhibition-reversible pathways. Methylecgonidine also stimulates M2 mAChRs, which couple to Gi/o proteins, leading to inhibition of (decreasing cAMP) and activation of guanylyl cyclase (increasing cGMP) in cellular models such as cultured human embryonic lung cells. These receptor interactions modulate intracellular Ca²⁺ dynamics, with muscarinic agonism reducing peak Ca²⁺ transients through mechanisms involving signaling, as atropine (1 μM, pA₂ = 9.17) competitively antagonizes effects without implicating local anesthetic-like Na⁺ channel blockade. Overall, these G-protein-coupled signaling cascades underlie methylecgonidine's profile, independent of direct monoaminergic transporter modulation.

Cardiovascular and Respiratory Effects

Methylecgonidine exerts negative inotropic effects on cardiac myocytes by reducing intracellular calcium transients and responsiveness to calcium, thereby decreasing . This action is mediated primarily through stimulation of muscarinic cholinergic receptors in the heart, contrasting with cocaine's sympathomimetic stimulation. studies in sheep following intravenous administration demonstrated cardiovascular responses consistent with muscarinic agonism, including mild in some subjects within 3 to 5 minutes post-injection, which was attenuated by prior atropine pretreatment. Methylecgonidine also enhances nitric oxide production in cultured neonatal rat cardiomyocytes, potentially contributing to altered calcium handling and long-term structural cardiac damage through oxidative stress pathways. On the respiratory system, methylecgonidine induces relaxation of airway smooth muscle in vitro, suggesting bronchodilatory potential that may facilitate deeper inhalation of crack cocaine smoke. This effect arises from its interaction with muscarinic receptors in bronchial tissue, though in vivo outcomes can vary with route of exposure, such as vapor inhalation versus systemic injection, showing overlapping autonomic influences on pulmonary function in animal models.

Toxicology

Acute and Neurotoxic Effects

Methylecgonidine, also known as anhydroecgonine methyl ester (AEME), induces acute in primary hippocampal neurons, reducing cell viability in a concentration- and time-dependent manner, with significant effects observed after 24 and 48 hours of exposure at micromolar concentrations. This exceeds that of , involving , mitochondrial dysfunction, and through DNA fragmentation. Mechanisms include partial agonism at M1 and M3 muscarinic receptors, which elevate (IP3) levels, disrupt cytosolic Ca²⁺ balance, and exacerbate production. Pretreatment with mitigates this viability loss, indicating a role for defense against AEME-mediated oxidative damage. In isolated cardiac myocytes from ferrets, methylecgonidine directly impairs Ca²⁺ , decreasing peak intracellular Ca²⁺ transients and contractile shortening in a dose-dependent manner across 10⁻⁸ to 10⁻⁴ M concentrations. These effects, mediated primarily via M₂ muscarinic receptor activation and blocked by atropine, contrast with cocaine's predominantly indirect sympathomimetic toxicity, as methylecgonidine's actions are more potent, shift Ca²⁺ responsiveness downward, and cause irreversible damage at higher doses without reliance on extracellular Ca²⁺ influx blockade. Cell culture models highlight methylecgonidine's cholinergic-like profile, with dose-response data underscoring direct cellular disruption rather than secondary systemic responses; for instance, viability assays in reveal IC₅₀ values in the low micromolar range for induction via muscarinic pathways. High-exposure paradigms evoke rapid neuronal membrane compromise and bioenergetic failure, though acute outcomes like convulsions remain linked more to combined crack pyrolysis products than isolated methylecgonidine.

Synergistic Toxicity with Cocaine

Methylecgonidine (AEME), formed during , exhibits synergistic neurotoxicity when co-administered with , particularly in hippocampal neurons. In rat primary hippocampal cell cultures, simultaneous exposure to AEME (10 μM) and (100 μM) induced rates exceeding additive expectations, with peaking at 24 hours post-exposure and persisting up to 48 hours, as measured by release and propidium iodide staining. This time-dependent potentiation involves enhanced activation of muscarinic receptors and pathways, amplifying 's standalone apoptotic effects beyond simple summation. The combination contributes to elevated cardiovascular risks observed in smoked cocaine relative to intranasal or intravenous routes, where AEME's negative inotropic effects compound 's sympathomimetic actions. In isolated hearts, AEME (1-10 μM) reduced contractility via muscarinic receptor agonism, and when paired with , this led to greater reductions in and increased arrhythmogenic potential compared to either agent alone. Human epidemiological data correlate crack smoking with higher incidences of and , attributable in part to AEME's additive bronchoconstrictive and hypotensive influences during co-inhalation. Preclinical studies from 2012 to 2021 demonstrate that AEME-cocaine mixtures amplify behavioral and neuronal in models. Repeated co-exposure heightened locomotor in rats, with AEME facilitating release in the beyond cocaine's effects, as evidenced by microdialysis and assays. This potentiation underscores AEME's role in the heightened liability and neurotoxic profile of smoking.

Comparative Toxicity to Parent Cocaine

Methylecgonidine, also known as anhydroecgonine methyl ester (AEME), demonstrates greater neurotoxic potential than parent in primary neuronal cultures. In hippocampal cell cultures, AEME exposure induced significantly higher than equivalent concentrations of , with viability assays showing reduced cell survival rates after 24 and 48 hours, and an additive toxic effect when both compounds were co-administered. This enhanced potency is attributed to AEME's dose-dependent activation of caspase-3 and other apoptotic pathways, exceeding those triggered by alone. AEME's toxicity profile differs mechanistically from 's, primarily through muscarinic rather than 's of monoamine transporters. AEME stimulates M1 and M3 muscarinic receptors, leading to unique endpoints such as disrupted synthesis in the rat , where it inhibits arylalkylamine N-acetyltransferase activity and reduces pinealocyte responsiveness, effects not observed with . Atropine, a , mitigates AEME-induced , confirming receptor mediation, whereas 's cardiovascular and neurotoxic effects stem predominantly from sympathetic overstimulation. A 2024 systematic review of AEME affirms its role in elevating the overall harm of over powder forms, via synergistic neurotoxic enhancement during respiratory absorption and distribution, including potentiated and dysregulation not prominent in non-pyrolyzed use. These findings indicate that introduces AEME as a key contributor to crack's augmented , distinct from cocaine's baseline profile.

Detection and Forensic Applications

Analytical Techniques

Gas chromatography-mass spectrometry (GC-MS) remains the reference standard for detecting and quantifying methylecgonidine (anhydroecgonine methyl ester, AEME) in biofluids like urine and plasma, offering high specificity through selected monitoring of fragment ions such as m/z 94 and m/z 136 after derivatization and . These methods achieve limits of detection () typically between 1 and 5 ng/mL in urine, enabling reliable identification even at low concentrations post-crack use. Validation involves assessing , precision (e.g., <15% relative standard deviation), and accuracy across calibration ranges of 5–1500 ng/mL. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) provides a complementary approach for high-throughput analysis, circumventing the thermal instability of methylecgonidine during gas-phase volatilization by direct liquid-phase ionization, often with electrospray interfaces and multiple reaction monitoring transitions (e.g., precursor-to-product ions confirmed via standards). This technique handles matrix interferences in plasma or urine via protein precipitation or online solid-phase extraction, yielding comparable LODs in the low ng/mL range while reducing sample preparation time. Sample stability poses a key challenge, as methylecgonidine undergoes rapid enzymatic and non-enzymatic hydrolysis to ecgonidine in biofluids, with a half-life of approximately 1 hour at physiological pH. To mitigate this, protocols recommend immediate acidification to pH 5.0–5.5 using phosphate buffers, addition of butyrylcholinesterase inhibitors such as sodium fluoride (1–2%), and storage at -20°C or lower; refrigerated samples at neutral pH show >50% loss within hours, underscoring the need for validated stabilization prior to extraction.

Use as a Biomarker for Crack Cocaine Consumption

Methylecgonidine, also known as anhydroecgonine methyl ester (AEME), is a pyrolysis product generated exclusively when cocaine base is heated during smoking, distinguishing it from other routes of cocaine administration such as snorting or injecting, where it is not formed. Its presence in biological matrices like urine provides unambiguous evidence of crack cocaine smoking, as confirmed in forensic and clinical analyses where methylecgonidine and its hydrolytic metabolite ecgonidine are absent in non-smokers. In a Danish laboratory study of 110 urine samples from suspected cocaine users, 84 (76.4%) tested positive for crack smoking via detection of these biomarkers, highlighting their specificity over general cocaine metabolites like benzoylecgonine. Quantitative ratios of methylecgonidine to in further support its use as a indicator; in verified crack smokers, the mean molar ratio of AEME to was 0.58, reflecting substantial pyrolysis-derived excretion comparable to parent drug levels, whereas such ratios approach zero in non-smokers. Detection in typically persists for 6–48 hours post-, aligning with rapid clearance (blood half-life of 18–21 minutes for methylecgonidine and 94–137 minutes for ecgonidine) but influenced by dose, hydration, and individual , shorter than the 2–4 days for . This temporal profile enables targeted verification in acute exposure scenarios. In forensic applications, methylecgonidine analysis of postmortem fluids and tissues differentiates as the in -related fatalities, aiding cause-of-death determinations by excluding artifactual formation. Workplace drug testing programs incorporate it to confirm smoking-specific use beyond standard cocaine positivity, enhancing compliance monitoring in high-risk professions. Population-level insights come from , where methylecgonidine concentrations track crack prevalence; a 2022 European study across 13 cities quantified spatial variations (e.g., higher in ) and temporal trends, correlating with self-reported data for the first time on this scale.

Historical and Research Context

Discovery and Early Studies

Methylecgonidine, also known as anhydroecgonine methyl ester, was first reported in 1990 as a unique product detected in the urine of individuals smoking base. Peyton Jacob III and colleagues identified it through gas chromatography-mass spectrometry (GC/MS) analysis of urine samples from controlled studies involving smokers, distinguishing it from metabolites like that predominate in non-smokers or those using other routes of administration. This finding emerged amid intensive research into the epidemic of the late 1980s and early 1990s, providing the first specific for smoked use. Early investigations in the mid-1990s further characterized its formation during crack heating. Studies demonstrated that methylecgonidine volatilizes in the vapor phase upon of base at temperatures typical of (around 600–900°C), subsequently condensing to coat the particulate matter inhaled by users. These experiments, using simulated smoking conditions, quantified methylecgonidine yields of up to 30–40% of the mass under optimal , emphasizing its prominence alongside unpyrolyzed in mainstream smoke. Initial pharmacokinetic profiling in these studies confirmed methylecgonidine's rapid systemic clearance following . Jacob et al. reported a plasma elimination of 15–20 minutes in crack smokers from controlled administrations, with to ecgonidine occurring quickly , yielding a longer of approximately 90–120 minutes for the . This profile, derived from serial blood and urine sampling, highlighted methylecgonidine's brevity as a marker compared to parent , informing early efforts to differentiate acute crack exposure in clinical and forensic contexts.

Recent Developments (2020–2025)

A 2024 systematic review synthesized evidence on the toxicokinetics and toxicodynamics of anhydroecgonine methyl ester (AEME), confirming its role as a primary product of smoked that contributes independently to the enhanced lethality of compared to other administration routes. The review highlighted AEME's activation of non-apoptotic pathways followed by apoptotic when combined with , leading to reduced neuronal viability and exacerbated in hippocampal cultures. A separate 2024 of and in vivo studies further established that exposure, via AEME formation, induces greater neurotoxic effects—such as , , and dopaminergic alterations—than intranasal or intravenous use. In 2021, research demonstrated AEME's synergistic contribution to cocaine-induced neuronal death in rat primary hippocampal cultures, with toxicity manifesting in a time-dependent manner: AEME alone reduced viability after 48 hours, while AEME-cocaine combinations accelerated cell death via additive oxidative damage and activation as early as 3-6 hours post-exposure. Pretreatment with mitigated AEME's effects by preserving glutathione-related enzyme activity and limiting , suggesting potential neuroprotective interventions against AEME-mediated damage. Wastewater-based in 2022 enabled the first broad-scale assessment of consumption across 13 European cities, using AEME as a stable (with in-sample stability confirmed and concentrations ranging from 1.8 to 36.6 ng/L). Population-normalized AEME loads showed no significant inter-city variations but revealed temporal fluctuations aligned with weekend peaks in use, providing empirical data on spatial trends in crack prevalence without relying on self-reported surveys. Ongoing investigations into AEME's cholinergic mechanisms, as detailed in the 2024 toxicology review, indicate its partial agonism at M1 and M3 muscarinic receptors, which may underlie neuroadaptation in dopaminergic systems and heightened addiction liability in crack users. These findings underscore AEME's distinct toxic profile beyond cocaine's parent effects, informing targeted research into smoked cocaine's unique health burdens.

References

  1. https://pubs.acs.org/doi/abs/10.1021/tx0255828
  2. https://pubmed.ncbi.nlm.nih.gov/39104366/
  3. https://pubmed.ncbi.nlm.nih.gov/2087095/
  4. https://www.smolecule.com/products/s570400
  5. https://pubmed.ncbi.nlm.nih.gov/14561847/
  6. https://www.sciencedirect.com/science/article/pii/0091305795001980
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC11298642/
  8. https://academic.oup.com/toxsci/article/128/1/223/1637206
  9. https://pubs.rsc.org/en/content/articlelanding/2017/tx/c7tx00009j
  10. https://jpet.aspetjournals.org/article/S0022-3565%2825%2924567-0/fulltext
  11. https://pubchem.ncbi.nlm.nih.gov/compound/119478
  12. https://www.chemspider.com/Chemical-Structure.106705.html
  13. https://www.caymanchem.com/product/17979/anhydroecgonine-methyl-ester
  14. https://www.chemicalbook.com/ChemicalProductProperty_US_CB8215239.aspx
  15. https://cdn.caymanchem.com/cdn/msds/17979m.pdf
  16. https://ntrs.nasa.gov/api/citations/19950026862/downloads/19950026862.pdf
  17. https://pubs.acs.org/doi/10.1021/acsomega.1c01325
  18. https://www.researchgate.net/publication/12259427_Stability_of_Methylecgonidine_and_Ecgonidine_in_Sheep_Plasma_in_Vitro
  19. https://www.researchgate.net/publication/262498638_Temperature-dependent_benzoic_acid_elimination_mechanisms_in_pyrolysis_of_--cocaine
  20. https://www.scielo.br/j/qn/a/t8qyzSwWz4yWNnxVDjf6NZG/?lang=en
  21. https://pubmed.ncbi.nlm.nih.gov/2755088/
  22. https://www.tandfonline.com/doi/pdf/10.3109/15563659008993484
  23. https://www.tandfonline.com/doi/pdf/10.1080/00304949709355202
  24. https://www.tandfonline.com/doi/abs/10.1080/00304949709355202
  25. https://pubs.acs.org/doi/10.1021/jo00019a044
  26. https://www.researchgate.net/publication/5442805_Pharmacokinetics_and_Pharmacodynamics_of_Methylecgonidine_a_Crack_Cocaine_Pyrolyzate
  27. https://patents.google.com/patent/US20030109708A1/en
  28. https://pubmed.ncbi.nlm.nih.gov/12501914/
  29. https://academic.oup.com/jat/article/39/6/451/756399
  30. https://www.nature.com/articles/srep17555
  31. https://pubmed.ncbi.nlm.nih.gov/11159694/
  32. https://pubmed.ncbi.nlm.nih.gov/9300320/
  33. https://pubmed.ncbi.nlm.nih.gov/9277508/
  34. https://journals.physiology.org/doi/pdf/10.1152/ajpheart.1997.273.2.H893
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC1573099/
  36. https://pubmed.ncbi.nlm.nih.gov/7891354/
  37. https://journals.lww.com/cardiovascularpharm/fulltext/1997/09000/negative_inotropic_effect_of_methylecgonidine%2C_a.13.aspx
  38. https://pmc.ncbi.nlm.nih.gov/articles/PMC6060695/
  39. https://journals.physiology.org/doi/full/10.1152/ajpheart.1997.273.2.H893
  40. https://www.sciencedirect.com/science/article/pii/S2214750024000738
  41. https://pubmed.ncbi.nlm.nih.gov/33674969/
  42. https://pubmed.ncbi.nlm.nih.gov/22523227/
  43. https://pubmed.ncbi.nlm.nih.gov/30090510/
  44. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/jms.975
  45. https://www.benchchem.com/product/b1201409
  46. https://pubmed.ncbi.nlm.nih.gov/8926742/
  47. https://pubs.acs.org/doi/10.1021/acsomega.3c09669
  48. https://www.researchgate.net/publication/262654414_A_study_on_the_stability_of_anhydroecgonine_methyl_ester_crack_biomarker_benzoylecgonine_and_cocaine_in_human_urine
  49. https://pubmed.ncbi.nlm.nih.gov/25868555/
  50. https://www.sciencedirect.com/science/article/abs/pii/S0022356524310717
  51. https://www.researchgate.net/publication/11963709_Examination_of_Postmortem_Fluids_and_Tissues_for_the_Presence_of_Methylecgonidine_Ecgonidine_Cocaine_and_Benzoylecgonine_Using_SolidPhase_Extraction_and_Gas_Chromatography-Mass_Spectrometry
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC3163103/
  53. https://pubmed.ncbi.nlm.nih.gov/35901880/
  54. https://academic.oup.com/jat/article-abstract/14/6/353/757149
  55. https://pubmed.ncbi.nlm.nih.gov/38769171/
  56. https://www.researchgate.net/publication/349832825_Anhydroecgonine_methyl_ester_a_cocaine_pyrolysis_product_contributes_to_cocaine-induced_rat_primary_hippocampal_neuronal_death_in_a_synergistic_and_time-dependent_manner
  57. https://www.sciencedirect.com/science/article/abs/pii/S0048969722043200
Add your contribution
Related Hubs
User Avatar
No comments yet.